Screening for celiac disease in asymptomatic children with Down syndrome: Cost-effectiveness of preventing lymphoma

Pediatrics

Volumn 118, Issue 2, 2006, Pages 594-602

  Swigonski, Nancy L ^a,b   Kuhlenschmidt, Heather L ^a   Bull, Marilyn J ^a   Corkins, Mark R ^a   Downs, Stephen M ^a  

^a INDIANA UNIVERSITY   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Celiac disease; Cost effectiveness; Down syndrome

Indexed keywords

ARTICLE; CELIAC DISEASE; COST EFFECTIVENESS ANALYSIS; DOWN SYNDROME; ENDOSCOPY; HISTOPATHOLOGY; HOSPITAL COST; HUMAN; INTESTINE BIOPSY; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; SEROLOGY; CHILD; COMORBIDITY; COST; COST BENEFIT ANALYSIS; DECISION TREE; DISEASE PREDISPOSITION; ECONOMICS; GASTROINTESTINAL TUMOR; MASS SCREENING; MEDICAID; MEDICARE; PREVALENCE; REIMBURSEMENT; RISK; STATISTICS; THEORETICAL MODEL;

CELIAC DISEASE; CHILD; COMORBIDITY; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION TREES; DISEASE SUSCEPTIBILITY; DOWN SYNDROME; GASTROINTESTINAL NEOPLASMS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LYMPHOMA, NON-HODGKIN; MASS SCREENING; MEDICAID; MEDICARE; MODELS, THEORETICAL; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RISK; SENSITIVITY AND SPECIFICITY;

EID: 33748436409     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2123     Document Type: Article

References (42)

1. Hill ID, Dirks MH, Liptak GS, et al. North American Society for Pediatric Gastroenterology HaN. Guideline for the Diagnosis and Treatment of Celiac Disease in Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40:1-19.
2. Bonamico M, Mariani P, Danesi HM, et al. Prevalence and clinical picture of celiac disease in Italian down syndrome patients: a multicenter study. J Pediatr Gastroenterol Nutr. 2001;33:139-143
3. Book L, Hart A, Black J, Feolo M, Zone JJ, Neuhausen SL. Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study. Am J Med Genet. 2001;98:70-74
4. Carlsson A, Axelsson I, Borulf S, et al. Prevalence of IgA-antigliadin antibodies and IgA-antiendomysium antibodies related to celiac disease in children with Down syndrome. Pediatrics. 1998;101:272-275
5. Bonamico M, Mariani P, Danesi HM, et al. Prevalence of celiac disease in Down's syndrome. J Gastroenterol Hepatol. 2001;33:263-267
6. Cohen W. Health care guidelines for individuals with Down syndrome: 1999 revision. Down Synd Q. 1999;4:1-15
7. Maki M, Mustalahti K, Kokkonen J, et al. Prevalence of Celiac disease among children in Finland. N Engl J Med. 2003;348:2517-2524
8. Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA. 2002;287:1413-1419
9. Hoffenberg E, Emery L, Barriga K, et al. Clinical features of children with screening-identified evidence of celiac disease. Pediatrics. 2004;113:1254-1259
10. Carnicer J, Farre C, Varea V, Vilar P, Moreno J, Artigas J. Prevalence of coeliac disease in Down's syndrome. Eur J Gastroenterol Hepatol. 2001;13:263-267
11. West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut. 2003;52:960-965
12. Catassi C, Fabiani E, Ratsch IM, et al. The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl. 1996;412:29-35
13. Holmes GK, Prior P, Lane M, Pope D, Allan RN. Malignancy in coeliac disease: effect of a gluten free diet. Gut. 1989;30:333-338
14. Fabiani E. Dietary compliance in screening-detected coeliac disease adolescents. Acta Paediatr. 1996;41(suppl):65-67
15. Greco L, Mayer M, Ciccarelli G, Troncone RSA. Compliance to a gluten-free diet in adolescents, or "what do 300 coeliac adolescents eat every day?" Ital J Gastroenterol Hepatol. 1997;29:305-310
16. Askling J, Linet M, Gridley G, Halstensen T, Ekstrom K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123:1428-1435
17. Hermon C, Alberman E, Beral V, Swerdlow AJ. Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. Ann Hum Genet. 2001;65:167-176
18. Hill DA, Gridley G, Cnattingius S, et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med. 2003;163:705-711
19. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359:1019-1025
20. Gold MR, Siegel JF, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
21. Weinstein M, Fineberg H. Clinical Decision Analysis. Philadelphia, PA: W.B. Saunders Co; 1980
22. DATA4. Decision Analysis [computer program]. Willimstown, MA: TreeAge Software, Inc; 1997
23. Atkinson K, Tamakajian S, Watson W, Grejor J. Evaluation of the endomysial antibody for celiac disease: operating properties and associated cost implications in clinical practice. Can J Gastroenterol. 1997;11:673-677
24. Coeliac Disease Study Group Service Laboratory. 6/10/2003. Available at: www.uta.fi/~llmama/cdserlab/. Accessed November 29, 2004
25. Medicare Reimbursement. Available at: www.cms.hhs.gov/providers/ pufdownload. Accessed April 20, 2005
26. Indiana Health Coverage Programs Fee Schedule. Available at: www.indianamedicaid.com/ihcp/Publications/MaxFee/fee_home.asp. Accessed June 10, 2005
27. Gluten-free market. Available at: http://glutenfreemarket.com/store/ enter.html. Accessed April 17, 2005
28. Net grocer. Available at: www.netgrocer.com. Accessed April 17, 2005
29. Costs of care first year after diagnosis. Available at: http://progressreport.cancer.gov/doc.asp?pid=1&did=21&chid=13&coid= 33&mid=vpco. Accessed April 28, 2005
30. Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment: Celiac Disease. Washington, DC: Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2004
31. Pueschel SM, Romano C, Failla P, et al. A prevalence study of celiac disease in persons with Down syndrome residing in the United States of America. Acta Paediatr. 1999;88:953-956
32. George EK, Mearin ML, Bouquet J, et al. High frequency of celiac disease in Down syndrome. J Pediatr. 1996;128:555-557
33. Friedman JM. Racial disparities in median age at death of persons with down syndrome: United States, 1968-1997. MMWR Morb Mortal Wkly Rep. 2001;50:463-465
34. Janicki MP, Dalton AJ, Henderson CM, Davidson PW. Mortality and morbidity among older adults with intellectual disability: health services considerations. Disabil Rehabil. 1999;21:284-294
35. Howdle PD, Jalal PK, Holmes GK, Houlston RS. Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM. 2003;96:345-353
36. Lymphoma. Available at: http://seer.cancer.gov/publications/ethnicity/ lymphoma.pdf. Accessed May 2, 2005
37. Hallert C, Granno C, Grant C, et al. Quality of life of adult coeliac patients treated for 10 years. Scand J Gastroenterol. 1998;33:933-938
38. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in the Netherlands. Eur J Haematol. 2005;74:194-202
39. Primer on cost-effectiveness analysis. Eff Clin Pract. 2003;3:253-255
40. National Institutes of Health. Department of Health and Human Services. NIH Consensus Development Conference on Celiac Disease. Available at: http://consensus.nih.gov/2004/2004 CeliacDisease118html.htm. Accessed January 15, 2005
41. Harewood GC, Murray JA. Diagnostic approach to a patient with suspected celiac disease: a cost analysis. Dig Dis Sci. 2001;46:2510-2514
42. Mein S, Ladabaum U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2004;19:1199-1210